Brain cancer fog: could a common antidepressant boost thinking?
NCT ID NCT03728673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether escitalopram, a common antidepressant, can improve thinking and memory problems in people with a severe type of brain tumor called grade IV glioma. Up to 85% of these patients struggle with cognitive issues from the tumor or its treatment. The study will give 20 participants the drug for 17 weeks and measure changes in cognition, mood, and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a sharper beam of radiation shield the mind during brain tumor treatment?
- Can a tiny implant trap brain tumor cells and make radiation work better?
- Can a targeted pill slow brain tumor growth after surgery?
- Brain surgery gets a GPS: network maps may help remove tumors while preserving function